Epitope-beta microglobulin polynucleotide for anti-cancer immunotherapy
CA 2463623 A1 · Owner: Isis Innovation Limited · Inventors: Mcmichael, Andrew James; Meier, Ute-Christiane; Layton, Guy
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention relates to polynucleotides for use in cancer therapy. In particular, the invention provides a polynucleotide capable of expressing an epitope-.beta.2m fusion protein; for use in the generation of cytotoxic T lymphocyte (CTL) responses against a tumour; and a polynucleotide capable of expressing an epitope-.beta.2m fusion protein; for use in a method of restoring antigen presentation in the tumour of a host.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed November 1, 2001. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended November 1, 2021.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by November 1, 2023.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.